{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bada HS"],"funding":["NCATS NIH HHS","NIDA NIH HHS"],"pagination":["e2023065610"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11524040"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["154(5)"],"pubmed_abstract":["<h4>Objective</h4>We sought to determine whether clonidine, a non-opioid α-2-adrenergic agonist, would effectively treat neonatal opioid withdrawal syndrome (NOWS).<h4>Methods</h4>This was an intention-to-treat randomized clinical trial. Enrollment criteria included prenatal opioid exposure, age ≤7 days, gestational age ≥35 weeks, no other medical condition, and need for pharmacotherapy. Primary outcomes were length of treatment and neurobehavioral performance.<h4>Results</h4>A total of 1107 patients were screened for enrollment (645 ineligible, 91 parents or staff unavailable, 216 declined, 155 consented). Of 155 infants, 120 required treatment and were randomized to receive oral clonidine (n = 60) at 1 µg/kg/dose or morphine (n = 60), 0.06 mg/kg/dose, every 3 hours. Infants with no impro"],"journal":["Pediatrics"],"pubmed_title":["Clonidine as Monotherapy for Neonatal Opioid Withdrawal Syndrome: A Randomized Trial."],"pmcid":["PMC11524040"],"funding_grant_id":["UL1 TR001998","UL1 TR000445","R01 DA043519"],"pubmed_authors":["Bada HS","Charnigo R","Westgate PM","Pourcyrous M","Giannone P","Leggas M","Sithisarn T","Yolton K","Gibson J","Shearer-Miller J","Tang F"],"additional_accession":[]},"is_claimable":false,"name":"Clonidine as Monotherapy for Neonatal Opioid Withdrawal Syndrome: A Randomized Trial.","description":"<h4>Objective</h4>We sought to determine whether clonidine, a non-opioid α-2-adrenergic agonist, would effectively treat neonatal opioid withdrawal syndrome (NOWS).<h4>Methods</h4>This was an intention-to-treat randomized clinical trial. Enrollment criteria included prenatal opioid exposure, age ≤7 days, gestational age ≥35 weeks, no other medical condition, and need for pharmacotherapy. Primary outcomes were length of treatment and neurobehavioral performance.<h4>Results</h4>A total of 1107 patients were screened for enrollment (645 ineligible, 91 parents or staff unavailable, 216 declined, 155 consented). Of 155 infants, 120 required treatment and were randomized to receive oral clonidine (n = 60) at 1 µg/kg/dose or morphine (n = 60), 0.06 mg/kg/dose, every 3 hours. Infants with no impro","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2026-06-05T09:28:51.98Z","creation":"2026-05-15T03:12:52.858Z"},"accession":"S-EPMC11524040","cross_references":{"pubmed":["39403061"],"doi":["10.1542/peds.2023-065610"]}}